| abstract |
The use of matrix metalloproteinases, mutated and not mutated, for the preparation of pharmaceutical compositions useful in the treatment of pathologies assiciated with an accumulation of matrix bio-polymers and/or an excess of TIMPs (Tissue Inhibitors MetalloProteinases) is described; mutated matrix metalloproteinases, in which at least an aminoacid residue in a definite position in the protein, has been mutated into a hydrophilic and/or charged aminoacidic residue, obtaining an increased stability toward autoproteolysis are also described. |